Japan’s Healios Eyes First Approvals As It Progresses Regenerative Therapies

Healios, a Japanese regenerative medicine bioventure, expects to continue benefiting from a supportive regulatory environment in Japan as it progresses three clinical assets toward approval in the next few years, says CEO Dr. Hardy Kagimoto in an exclusive interview.

Following the modification and introduction of legislation governing the safety, development and use of regenerative and cell therapies in Japan in late 2014, companies in the space have been generally positive on the shape and impact of the supportive regulatory environment in the country – which has already led to the reimbursement and launch of several therapies.

Tokyo-based Healios K.K. is one such company. Formed in 2011 as Retina Institute Japan, a Fukuoka-based venture under Riken...

More from Global Vision

More from In Vivo